Gynecologic Cancers

One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.

The FDA has granted priority review to the new drug application for the novel compound pafolacianine sodium injection for use in the identification of ovarian cancer during surgery.

An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.

The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.

“Second-line maintenance therapy is going to be incredibly important for patients because we know that once a patient with ovarian cancer recurs, their disease is incurable."

Ursula Matulonis, MD, highlights immunotherapy agents have demonstrated moderate clinical activity for patients with gynecologic cancers, however they fail to yield significant response rates in both the newly-diagnosed and recurrent settings.

While PARP inhibitors have played a large part in improving progression-free survival (PFS) in patients with ovarian cancer, long-term use of these agents often leads to resistance that are often quite challenging to overcome, according to Gottfried E. Konecny, MD.

The FDA approved the CINtec PLUS Cytology test to help determine if HPV-positive women need further diagnostic procedures to prevent cervical cancer.

Cervical cancer is often diagnosed in the later stages, though incidence of the disease is declining thanks to the HPV vaccine.

Pap and HPV testing can decrease cervical cancer risk, but testing intervals seem to be sporadic for patients.

Pembrolizumab (Keytruda) demonstrated modest clinical activity in patients with advanced recurrent ovarian cancer, according to final results of the phase 2 KEYNOTE-100 trial that were presented during the 2020 ASCO Virtual Scientific Program.

The FDA has approved the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer.

The vaccine BVAC-C demonstrated durable antitumor activity in patients with HPV 16– or HPV 18–positive recurrent cervical cancer, according to findings presented at the 2020 AACR Virtual Annual Meeting I.

A reduction in patient-reported symptomatic adverse events (AEs) was observed with intensity-modulated radiotherapy (IMRT) compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AE.

The future looks to be defined by essential clinical trials.

The FDA approved niraparib for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to frontline platinum-based chemotherapy.

Retrospective results showed that African-American women with endometrial cancer are less likely to receive evidence-based care compared with white women.

The FDA has granted a Fast Track designation to the combination of the PD-1 inhibitor balstilimab and the CTLA-inhibitor zalifrelimab for the treatment of patients with relapsed or refractory metastatic cervical cancer.

The FDA has approved the CINtec® PLUS Cytology test as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the cobas® 4800 HPV Test, according to Roche (Genentech), the manufacturer of the test.

The FDA has accepted a biologics license application for a proposed biosimilar for bevacizumab (Avastin), according to an announcement by Mylan during its fourth quarter 2019 earnings call.

The FDA has accepted a supplemental New Drug Application (sNDA) for niraparib (Zejula) for use as a frontline maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status.

Study findings, “changed how we see and treat patients with ovarian cancer,” said one expert.

The FDA has granted a priority review for the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer.

An expert discusses how clinicians choose between PARP inhibitors for patients with ovarian cancer, and what may be coming next in the field.

Gynecologic cancers present some of the most dangerous cancer-related threats to women, here's how to help patients understand what to look out for and the realities of their treatment.

New real-world data shows that PARP inhibitors have the potential to help patients with ovarian cancer and could be an affordable option for them.

The FDA approves the use of niraparib in the treatment of patients with HRD-positive advanced ovarian cancer based on results from the phase II QUADRA study.

At the 2019 European Society for Medical Oncology, new study results showed promise for a frontline combination therapy for patients with newly diagnosed, advanced ovarian cancer.

A new study shows promising results for niraparib in the treatment of patients with ovarian cancer.

The FDA has granted accelerated approval to the combination of lenvatinib and pembrolizumab in the treatment of patients with advanced endometrial carcinoma.